TETRACOSACTIDE

DRUG3 trials

Sponsors

Heidelberg University Hospital AöR, Assistance Publique Hopitaux De Paris, Eupraxia Pharmaceuticals Inc.

Conditions

Critically ill patients suffering from CIRCIEosinophilic esophagitisTuberous sclerosis complex (TSC)

Phase 1

A Phase 1b/2 Trial Evaluating the Safety, Pharmacokinetics, and Efficacy of EP 104GI in Adults with Eosinophilic Esophagitis (RESOLVE)

RecruitingCTIS2024-516689-13-00

Eupraxia Pharmaceuticals Inc.Eosinophilic esophagitis

Start: 2023-02-06Target: 5Updated: 2025-08-19

Phase 2

Long-term neuropsychologic outcome of pre-emptive mTOR inhibitor treatment in children with tuberous sclerosis complex (TSC) under 4 months of age (PROTECT)

RecruitingCTIS2022-502332-39-00

Heidelberg University Hospital AöRTuberous sclerosis complex (TSC)

Start: 2023-11-15Target: 64Updated: 2025-08-25

Phase 3

HORNbILL. HydrOcortisone and fludRocortisoNe for critical ILLness-related corticosteroid insufficiency

CompletedCTIS2024-516021-32-00

Assistance Publique Hopitaux De ParisCritically ill patients suffering from CIRCI

Start: 2022-02-17End: 2025-11-09Target: 3276Updated: 2024-11-05

Related Papers

Long-term neuropsychologic outcome of pre-emptive mTOR inhibitor treatment in children with tuberous sclerosis complex (TSC) under 4 months of age (PROTECT), a two-arm, randomized, observer-blind, controlled phase IIb national multicentre clinical trial: study protocol.

2025-01-064 citations